Insider Trading Alert - CGIX, NI And XNCR Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, June 15, 2015, 81 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $428.00 to $1,771,500.00.

Highlighted Stocks Traded by Insiders:

Cancer Genetics (CGIX) - FREE Research Report

Chaganti Raju S.K., who is Director at Cancer Genetics, sold 7,000 shares at $12.01 on June 15, 2015. Following this transaction, the Director owned 176,977 shares meaning that the stake was reduced by 3.8% with the 7,000-share transaction.

The shares most recently traded at $11.90, down $0.11, or 0.9% since the insider transaction. Historical insider transactions for Cancer Genetics go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 71,037
  • 12-Week # shares bought: 10,000
  • 12-Week # shares sold: 71,037
  • 24-Week # shares bought: 61,000
  • 24-Week # shares sold: 71,037

The average volume for Cancer Genetics has been 83,500 shares per day over the past 30 days. Cancer Genetics has a market cap of $117.4 million and is part of the health care sector and health services industry. Shares are up 78.89% year-to-date as of the close of trading on Monday.

Cancer Genetics, Inc., an oncology diagnostics company, focuses on developing and commercializing DNA-based tests and services to enhance and personalize the diagnosis, prognosis, and treatment of targeted cancers in the United States, India, and China. Currently, there are 3 analysts who rate Cancer Genetics a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CGIX - FREE

TheStreet Quant Ratings rates Cancer Genetics as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow and feeble growth in its earnings per share. Get the full Cancer Genetics Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

NiSource (NI) - FREE Research Report

Parker Deborah S, who is Director at NiSource, sold 3,429 shares at $46.28 on June 15, 2015. Following this transaction, the Director owned 11,842 shares meaning that the stake was reduced by 22.45% with the 3,429-share transaction.

The shares most recently traded at $46.26, down $0.02, or 0.04% since the insider transaction. Historical insider transactions for NiSource go as follows:

  • 4-Week # shares sold: 4,500
  • 12-Week # shares bought: 1,000
  • 12-Week # shares sold: 4,500
  • 24-Week # shares bought: 1,000
  • 24-Week # shares sold: 12,308

The average volume for NiSource has been 2.1 million shares per day over the past 30 days. NiSource has a market cap of $14.6 billion and is part of the utilities sector and utilities industry. Shares are up 9.26% year-to-date as of the close of trading on Monday.

NiSource Inc., an energy holding company, provides natural gas, electricity, and other products and services in the United States. It operates through three segments: Gas Distribution Operations, Columbia Pipeline Group Operations, and Electric Operations. The stock currently has a dividend yield of 2.26%. The company has a P/E ratio of 27.5. Currently, there are 2 analysts who rate NiSource a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on NI - FREE

TheStreet Quant Ratings rates NiSource as a buy. The company's strengths can be seen in multiple areas, such as its increase in net income, good cash flow from operations and solid stock price performance. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full NiSource Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Xencor (XNCR) - FREE Research Report

Baracchini Edgardo Jr, who is Chief Business Officer at Xencor, sold 1,277 shares at $19.85 on June 15, 2015. Following this transaction, the Chief Business Officer owned 0 shares meaning that the stake was reduced by 100% with the 1,277-share transaction.

The shares most recently traded at $20.70, up $0.85, or 4.11% since the insider transaction. Historical insider transactions for Xencor go as follows:

  • 4-Week # shares sold: 28,756
  • 12-Week # shares sold: 30,960
  • 24-Week # shares sold: 30,960

The average volume for Xencor has been 203,700 shares per day over the past 30 days. Xencor has a market cap of $782.2 million and is part of the health care sector and drugs industry. Shares are up 20.82% year-to-date as of the close of trading on Monday.

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of engineered monoclonal antibodies to treat severe and life-threatening diseases with unmet medical needs. Currently, there are 3 analysts who rate Xencor a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on XNCR - FREE

TheStreet Quant Ratings rates Xencor as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share and deteriorating net income. Get the full Xencor Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you liked this article you might like

Liking the Look of Some of These Pullbacks

Liking the Look of Some of These Pullbacks

Heck With the NFL Draft; I'm Anxiously Awaiting a Big Earnings Night

Heck With the NFL Draft; I'm Anxiously Awaiting a Big Earnings Night

Don't Be Surprised If Dip Buyers Jump In on Any Pullback

Don't Be Surprised If Dip Buyers Jump In on Any Pullback

The Best Timeframe Right Now Is the Intraday Trade

The Best Timeframe Right Now Is the Intraday Trade

Health Care Vote Impacts Trump's Deal Maker Image

Health Care Vote Impacts Trump's Deal Maker Image